## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

#### SCHEDULE 13G

Under the Securities Exchange Act of 1934\*

(Amendment No. 1)

Alexion Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock, \$0.0001 par value

(Title of Class of Securities)

015351109

(CUSIP Number)

December 31, 2005

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- [ ] Rule 13d-1(b)
- [X] Rule 13d-1(c)
- [ ] Rule 13d-1(d)

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No.	01535110			13G	Page	2	of	 7	Pages			
1			NG PERSON IDENTIFICATION									
	Duquesne Capital Management, L.L.C.											
2	CHECK THI	E APPRO	PRIATE BOX IF 1	A MEMBER OF	A GROU	P*			a) [ ] b) [X]			
3	SEC USE (	ONLY										
4	CITIZENSHIP OR PLACE OF ORGANIZATION											
	Pennsylvania											
		5	SOLE VOTING I	POWER								
			0									
NUMBI	ER OF	6	SHARED VOTING	G POWER								

SHARES

OWNED BY  EACH  REPORTING			203,322
1	PERSON	7	SOLE DISPOSITIVE POWER
	WITH		0
		8	SHARED DISPOSITIVE POWER
			203,522
9	AGGREGATE	AMOUNT	BENEFICIALLY OWNED BY EACH REPORTING PERSON
	203,522		
10	CHECK BOX	IF THE	AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
	N/A		
11	PERCENT O	F CLASS	REPRESENTED BY AMOUNT IN ROW 9
	0.7%		
12	TYPE OF R	EPORTIN	G PERSON*
	00		

203,522

BENEFICIALLY

CUSIP No.	015351109			13G	Page	3	of	7	Pages	
1	NAME OF RES.S. OR I		G PERSON DENTIFICATION NO	. OF ABO	VE PERS	ON				
	Stanley F. Druckenmiller									
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*  (a) [ ]  (b) [X]									
3	SEC USE ONLY									
4	CITIZENSH	IP OR P	LACE OF ORGANIZA	TION						
	United Sta	ates								
		5	SOLE VOTING POW	ER						
			0							
	NUMBER OF 6 SHARES BENEFICIALLY OWNED BY EACH		SHARED VOTING POWER							
BENEFIC OWNEI EAC			203,522							
PERS		7	SOLE DISPOSITIVE POWER							
TIW	TH .		0							
		8	SHARED DISPOSITIVE POWER							
			203,522							
9	AGGREGATE	AMOUNT	BENEFICIALLY OW	NED BY E	ACH REE	ORTI	NG F	ERS	 ON	
	203,522									
10	CHECK BOX		AGGREGATE AMOUN			CLUD	ES C	ERT	AIN SHARES*	
	N/A									
11	PERCENT O	F CLASS	REPRESENTED BY	AMOUNT I	N ROW 9	)				
	0.7%									
12	TYPE OF REPORTING PERSON*									
	IN									

CUSIP No.	015351109			13G	Page	4	of 	7 	Pages	
1	NAME OF RI S.S. OR I Steeler Fr	.R.S. II	DENTIFICATION NO.	OF ABOV	E PERS					
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*  (a) [ ]  (b) [X]									
3	SEC USE O	NLY								
4	CITIZENSH	IP OR P	LACE OF ORGANIZAT	'ION						
	Cayman Isi	lands								
		5	SOLE VOTING POWE							
SHAI BENEFIC OWNEI EAC REPOI PERS	NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		SHARED VOTING PC  0  SOLE DISPOSITIVE							
			0 							
9	AGGREGATE	AMOUNT	BENEFICIALLY OWN			ORTII	 NG P	 ERS(	DN	
10	CHECK BOX	IF THE	AGGREGATE AMOUNT			CLUDI	ES C	ERTA	AIN SHARES*	
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9									
12	TYPE OF REPORTING PERSON*									

This Amendment No. 1 to Schedule 13G (this "Amendment No. 1") is being filed with respect to the Common Stock of Alexion Pharmaceuticals, Inc., a corporation organized under the laws of the State of Delaware, to amend the Schedule 13G filed on October 21, 2005 (the "Schedule 13G") and to report beneficial ownership of less than 5% of the total outstanding Common Stock. Capitalized terms used but not defined herein have the meaning ascribed thereto in the Schedule 13G.

Item 4: Ownership:

#### A. Duquesne Capital

- (a) Amount beneficially owned: 203,522.
- (b) Percent of class: 0.7%. The percentages used herein and in the rest of this Schedule 13G are calculated based upon a total of 30,914,583 shares of Common Stock issued and outstanding as of November 30, 2005, as reflected in the Company's Quarterly Report on Form 10-Q for the fiscal quarter ended October 31, 2005.
- (c) Number of shares as to which such person has:
  - (i) Sole power to vote or direct the vote: -0-
  - (ii) Shared power to vote or direct the vote: 203,522
  - (iii) Sole power to dispose or direct the disposition: -0-
  - (iv) Shared power to dispose or direct the disposition: 203,522

#### B. Mr. Druckenmiller

-----

- (a) Amount beneficially owned: 203,522
- (b) Percent of class: 0.7%.
- (c) Number of shares as to which such person has:
  - (i) Sole power to vote or direct the vote: -0-
  - (ii) Shared power to vote or direct the vote: 203,522
  - (iii) Sole power to dispose or direct the disposition: -0-
  - (iv) Shared power to dispose or direct the disposition: 203,522

#### C. Steeler

-----

- (a) Amount beneficially owned: -0-
- (b) Percent of class: 0.0%.
- (c) Number of shares as to which such person has:
  - (i) Sole power to vote or direct the vote: -0-
  - (ii) Shared power to vote or direct the vote: -0-
  - (iii) Sole power to dispose or direct the disposition: -0-
  - (iv) Shared power to dispose or direct the disposition: -0-

### Item 5: Ownership of Five Percent or Less of a Class:

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: [X]

# Item 10: Certification:

Each Reporting Person hereby makes the following certification:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

#### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

DATED: February 8, 2006

DUQUESNE CAPITAL MANAGEMENT, L.L.C.

By: /s/ Gerald Kerner

\_\_\_\_\_

Name: Gerald Kerner Title: Managing Director

STANLEY F. DRUCKENMILLER

By: /s/ Gerald Kerner

\_\_\_\_\_

Name: Gerald Kerner Title: Attorney-in-Fact

STEELER FUND, LTD.

By: Duquesne Capital Management, L.L.C.,

its investment manager

By: /s/ Gerald Kerner

-----

Name: Gerald Kerner Title: Managing Director

[SIGNATURE PAGE TO AMENDMENT NO. 1 TO SCHEDULE 13G WITH RESPECT TO ALEXION PHARMACEUTICALS, INC.]